Interestingly, GcfAB-immune mice inoculated via IN or SL routes generally showed lower levels of both eosinophilia and body weight loss following RSV B infection, indicating that GcfAB vaccination can protect against RSV B subtype without vaccine-induced immunopathology, in contrast with RSV A. Accordingly, G/183-195 of RSV B-specific CD4 T-cell responses were weak compared with those in the RSV A challenge groups. This evidence concerns the gene CD4 and Increased total eosinophil count.